Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Prof. Siefker-Radtke on the EV-103 trial in bladder cancer

Arlene Siefker-Radtke • 28 Sep 2019
ESMO 2019
Bladder Cancer Genitourinary Cancer Antibodies Enfortumab vedotin Pembrolizumab
EV-103

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses her thoughts on the latest news in bladder cancer at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain – the EV-103 trial of enfortumab vedotin combined with pembrolizumab (NCT03288545).

More from Arlene Siefker-Radtke

1:47
The future role of erdafitinib in advanced urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:34
RAGNAR: histology-agnostic trial of erdafitinib in FGFR3-mutant tumors
Arlene Siefker-Radtke • 4 Jun 2023
2:34
NORSE: erdafitinib and cetrelimab in urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:15
What role will erdafitinib play in treating metastatic urothelial carcinoma?
Arlene Siefker-Radtke • 4 Jun 2023

Related Videos

0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
0:38
Emerging combinatory immunotherapies show promise for mCRPC
Hannah McManus • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals